Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E–mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary ana...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Tabernero, Josep, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod Kyrre, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Elez, Elena, Gollerkeri, Ashwin, Maharry, Kati, Christy-Bittel, Janna, Kopetz, Scott
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2021
נושאים:
RAPID COMMUNICATIONS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078423/
https://ncbi.nlm.nih.gov/pubmed/33503393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02088
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים